DBV Technologies' (DBVT) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reissued their market outperform rating on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a research note released on Friday,Benzinga reports. They currently have a $10.00 price target on the stock.

A number of other brokerages have also recently commented on DBVT. HC Wainwright boosted their price target on DBV Technologies from $25.00 to $35.00 and gave the stock a "buy" rating in a research report on Thursday, October 24th. StockNews.com assumed coverage on DBV Technologies in a research report on Thursday. They issued a "hold" rating on the stock.

DBV Technologies Trading Up 29.8 %

DBV Technologies stock traded up $1.14 during trading hours on Friday, hitting $4.97. 798,039 shares of the stock traded hands, compared to its average volume of 351,584. The firm's 50-day moving average price is $3.32 and its two-hundred day moving average price is $3.83. The company has a market cap of $102.23 million, a PE ratio of -1.10 and a beta of 0.64. DBV Technologies has a one year low of $2.20 and a one year high of $9.49.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.